The CERTAIN Registry: A Novel, Web-Based Registry and Research Platform for Pediatric Renal Transplantation in Europe

Plotnicki, L.; Kohl, Christian; Höcker, Britta; Krupka, Kai; Rahmel, Axel; Pape, Lars; Hoyer, P.F.; Marks, Stephen D.; Webb, N. J. A.; Söylemezoğlu, Oğuz; Topaloğlu, Rezan; Szabó, Alexandra; Seeman, Tomáš; Cornelissen, Elisabeth A.M.; Knops, Noël; Grenda, Ryszard; Tönshoff, Burkhard

doi:10.1016/j.transproceed.2013.01.007

Cited by 37 publications

(24 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This retrospective cohort study analyzed data reported to the CERTAIN Registry (http://www.certain-registry.eu). The CERTAIN Registry is based on a detailed and comprehensive data capture to allow an in‐depth characterization of specific patient cohorts. Within the registry, a broad set of anthropometric, biochemical, disease‐, and medication‐related data is collected.…”

Section: Methodsmentioning

confidence: 99%

Dyslipidemia after pediatric renal transplantation—The impact of immunosuppressive regimens

Habbig

Volland

Krupka

et al. 2017

Pediatric Transplantation

View full text Add to dashboard Cite

Dyslipidemia contributes to cardiovascular morbidity and mortality in pediatric transplant recipients. Data on prevalence and risk factors in pediatric cohorts are, however, scarce. We therefore determined the prevalence of dyslipidemia in 386 pediatric renal transplant recipients enrolled in the CERTAIN registry. Data were obtained before and during the first year after RTx to analyze possible non-modifiable and modifiable risk factors. The prevalence of dyslipidemia was 95% before engraftment and 88% at 1 year post-transplant. Low estimated glomerular filtration rate at 1 year post-transplant was associated with elevated serum triglyceride levels. The use of TAC and of MPA was associated with significantly lower concentrations of all lipid parameters compared to regimens containing CsA and mTORi. Immunosuppressive regimens consisting of CsA, MPA, and steroids as well as of CsA, mTORi, and steroids were associated with a three- and 25-fold (P<.001) increased risk of having more than one pathologic lipid parameter as compared to the use of TAC, MPA, and steroids. Thus, amelioration of the cardiovascular risk profile after pediatric RTx may be attained by adaption of the immunosuppressive regimen according to the individual risk profile.

show abstract

Section: Methodsmentioning

confidence: 99%

Dyslipidemia after pediatric renal transplantation—The impact of immunosuppressive regimens

Habbig

Volland

Krupka

et al. 2017

Pediatric Transplantation

View full text Add to dashboard Cite

show abstract

“…Owing to its detailed and comprehensive data capture, this registry enables an in-depth characterization of specific patient cohorts (17). CMV-specific data collection for this analysis was performed according to a defined protocol (additional Supporting Information may be found in the online version of this article).…”

Section: Study Design and Patient Populationmentioning

confidence: 99%

“…In the CERTAIN Registry, data are automatically validated in the dataentry phase (17). Beyond this, all documented data undergo a manual quality assurance process: First, a documented data set requires local approval by the supervising physician on site; second, the data quality manager in the Registry headquarters verifies data plausibility before incorporation into the CERTAIN data repository.…”

Section: Data Validation Processmentioning

confidence: 99%

Impact of Everolimus and Low-Dose Cyclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation

Höcker

Zencke

Pape

et al. 2016

American Journal of Transplantation

Self Cite

View full text Add to dashboard Cite

These authors contributed equally to the study.In order to investigate the hypothesis that the mammalian target of rapamycin inhibitor everolimus (EVR) shows anticytomegalovirus (CMV) activity in pediatric patients, we analyzed the impact of EVRbased immunosuppressive therapy on CMV replication and disease in a large cohort (n = 301) of pediatric kidney allograft recipients. The EVR cohort (n = 59), who also received low-dose cyclosporin, was compared with a control cohort (n = 242), who was administered standard-dose cyclosporin or tacrolimus and an antimetabolite, mostly mycophenolate mofetil (91.7%). Multivariate analysis revealed an 83% lower risk of CMV replication in the EVR cohort than in the control cohort (p = 0.005). In CMV high-risk (donor+/recipientÀ) patients (n = 88), the EVR-based regimen was associated with a significantly lower rate of CMV disease (0% vs. 14.3%, p = 0.046) than the standard regimen. In patients who had received chemoprophylaxis with (val-) ganciclovir (n = 63), the CMV-free survival rates at 1 year and 3 years posttransplant (100%) were significantly (p = 0.015) higher in the EVR cohort (n = 15) than in the control cohort (n = 48; 1 year, 75.0%; 3 years, 63.3%). Our data suggest that in pediatric patients at high risk of CMV, an EVR-based immunosuppressive regimen is associated with a lower risk of CMV disease than a standard-dose calcineurin inhibitor-based regimen.

show abstract

“…We currently cannot predict which patients with DSA will develop AMR and chronic allograft injury and dysfunction, so collaborative research is required to define the optimal biomarkers of renal allograft injury prior to the development of renal allograft dysfunction [12]. In the next few years, there should be results from multi-center randomized controlled trials in pediatric and adult RTR to answer the questions if bortezomib has a role in RTR with high titer DSA prior to the development of AMR and in those with early or late established AMR as well as an induction agent in sensitized RTR.…”

Section: Discussionmentioning

confidence: 99%

The lack of Lazarus effect with proteasome inhibition

Marks

2016

Pediatr Nephrol

View full text Add to dashboard Cite

There have been marked improvements in the short-and long-term outcomes for children after renal transplantation over the past two decades with superior quality and quantity of life. It is encouraging to see increased patient and renal allograft survival rates with initially lower acute renal allograft rejection rates due to improved matching and immunosuppressive regimens. Unfortunately, longer-term renal allograft survival remains unchanged with chronic allograft injury from both immune and non-immune causes, resulting in chronic allograft dysfunction, morbidity from chronic kidney disease, and eventual renal allograft loss. Acute and chronic antibody-mediated rejection remains a clinical dilemma with a growing evidence base of its treatment, including proteasome inhibition using intravenous bortezomib. The future goal is to reduce chronic allograft dysfunction and make renal transplants last longer for pediatric renal transplant recipients who may require retransplantation during their childhood and adult lives, which can become successively more difficult due to sensitization.

show abstract

The CERTAIN Registry: A Novel, Web-Based Registry and Research Platform for Pediatric Renal Transplantation in Europe

Cited by 37 publications

References 3 publications

Dyslipidemia after pediatric renal transplantation—The impact of immunosuppressive regimens

Dyslipidemia after pediatric renal transplantation—The impact of immunosuppressive regimens

Impact of Everolimus and Low-Dose Cyclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation

The lack of Lazarus effect with proteasome inhibition

Contact Info

Product

Resources

About